 |
|
Immunosuppression and Skin Cancer
Pathogenetic Insights, Therapeutic Challenges, and Opportunities for Innovation
Arch Dermatol. 2002;138:827-828.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
THE PAST 30 years have seen unprecedented growth in the numbers of immunosuppressed
patients, with iatrogenic and disease-related immunosuppression. Approximately
100 000 US citizens undergo long-term immunosuppression to preserve life-sustaining
solid organ allografts. Worldwide, 36.1 million people are estimated to be
living with the human immunodeficiency virus (HIV) or the acquired immunodeficiency
syndrome. Chronic lymphocytic leukemia (CLL) affects approximately 81 000
patients per year in the United States, resulting in a prolonged immunocompromised
status. To a lesser degree, patients with inflammatory disorders of the cutaneous
and musculoskeletal systems may undergo long-term immunosuppression with therapeutic
medications. Finally, we are entering an era of exploration in the use of
biologic response modifiers and antibody-mediated immunomodulation with unknown
long-term effects.
Soon after successful solid organ allograft preservation was achieved
with profound immunosuppression, significantly increased risks of infectious
and neoplastic complications were noted. Skin cancer is the most common malignancy
in the posttransplantation setting, with squamous . . . [Full Text of this Article]
RELATED ARTICLE
Aggressive Squamous Cell Carcinomas in Persons Infected With the Human Immunodeficiency Virus
Patricia Nguyen, Kirsten Vin-Christian, Michael E. Ming, and Timothy Berger
Arch Dermatol. 2002;138(6):758-763.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Consensus Statement on the Use of Intravenous Immunoglobulin Therapy in the Treatment of Autoimmune Mucocutaneous Blistering Diseases
Ahmed and Dahl
Arch Dermatol 2003;139:1051-1059.
ABSTRACT
| FULL TEXT
|
